Instil Bio Return on Equity

Instil Bio (TIL) currently reports a ROE of -28.2%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Instil Bio's ROE history and peer comparisons.

Instil Bio's ROE of -28.2% is higher than the Healthcare sector average of -75.84%. That is roughly 62.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Instil Bio's current -28.2% should be judged against Healthcare norms (sector average: -75.84%) and against TIL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -28.2%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Instil Bio, and consider following TIL for alerts when major investors trade the stock.

Instil Bio is classified in the Healthcare sector. On ROE, it currently shows -28.2% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TIL with unrelated industries.